ORAL AND INJECTABLE LONG-LASTING BROMOCRIPTINE PREPARATIONS IN HYPERPROLACTINEMIA - COMPARISON OF THEIR PROLACTIN LOWERING ACTIVITY, TOLERABILITY AND SAFETY

被引：4

作者：

MEROLA, B ^{[1
]}

COLAO, A ^{[1
]}

CARUSO, E ^{[1
]}

SARNACCHIARO, F ^{[1
]}

BRIGANTI, F ^{[1
]}

LANCRANJAN, I ^{[1
]}

LOMBARDI, G ^{[1
]}

SCHETTINI, G ^{[1
]}

机构：

[1] NAPLES UNIV,SCH MED 2,CHAIR ENDOCRINOL,I-80138 NAPLES,ITALY

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1991年 / 5卷 / 04期

关键词：

D O I：

10.3109/09513599109028448

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bromocriptine, a D2 receptor agonist, has been widely used in tumoral and non-tumoral hyperprolactinemia, in reducing both plasma prolactin levels and in restoring fertility and/or menses in most patients. In this study a comparison between the injectable repeatable and the oral slow release formulations of bromocriptine (Parlodel LAR(R) and Parlodel SRO(R)) is reported, with respect to their effectiveness, tolerability and safety. Eleven patients with hyperprolactinemia, submitted to both treatments, were studied for a period of 1-24 months. Among the four patients with macroprolactinoma, three reached normoprolactinemia without complaining of side-effects, with both formulations, while the remaining patient became intolerant of the oral form after 1 year, and is presently being treated with the injectable formulation without presenting any side-effects. Among the five patients with microprolactinoma, two patients had a good response to both drugs; two patients did not reach normoprolactinemia with the injectable formulations, but a progressive decrease of prolactin levels was obtained with Parlodel SRO therapy, and the remaining patient was completely intolerant of the oral form without complaining of side-effects with Parlodel LAR. Two patients had non-tumoral hyperprolactinemia: one was intolerant of both drugs and one tolerated both formulations very well. In conclusion, Parlodel LAR and Parlodel SRO are very effective compounds in the medical treatment of hyperprolactinemic syndromes. The availability of these differing formulations improves the medical therapy, allowing a better choice of therapeutic regimen according to the effectiveness of, and tolerability to, the different drug formulations. In this way also, with poorly tolerant patients, it is possible to choose the better tolerated and more effective formulation of the drug.

引用

页码：267 / 276

页数：10

共 13 条

[1]

Desmond G., Johnston D.G., Prescott K.W.J., Kendall-Taylor P., Hall K., Crombie A.L., Hyperprolactinemia. Long-term effects of bromocriptine, Am J. Med, 75, (1983)

[2]

Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Jeffrey C., Jaffe R., Jopum G., Robbins R.J., Tyson J., Thorner M.O., Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicentric study, J. Clin. Endocrinol. Metab, 60, (1985)

[3]

Liuzzi A., Dallabonzana D., Oppizzi G., Verde C.G., Cozzi R., Chiodini P.G., Lucarelli G., Low doses of dopamine agonists in the long-term treatment of macroprolactinomas, N. Engl. J. Med, 313, (1985)

[4]

Thorner M.O., Martin W.H., Rogol A.D., Morris J.L., Perryman R.L., Conway B.P., Howards S.S., Wolfman M.G., MacLeod K.M., Rapid regression of pituitary prolactinomas during bromocriptine treatment, J. Clin. Endocrinol. Metab, 51, (1980)

[5]

Spark R.F., Baker R., Bienfang D.C., Bergland K., Bromocriptine reduces pituitary tumor size and hypersecretion. Requiem for pituitary surgery?, J. Ant. Med. Assoc, 247, (1982)

[6]

Velentzas C., Carras O., Vassilourhis J., Regression of pituitary prolactinomas with bromocriptine administration, J. Am. Med. Assoc, 245, (1983)

[7]

Lancranjan I., Rolland R., L'Hermite M., Inhibition of lactation with depot-bromocriptine, Ann. NY. Acad. Sci, 115, (1987)

[8]

Merola B., Colao A., Caruso E., Sarnacchiaro F., Lancranjan I., Lombardi G., Schettini G., Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia, J. Endocrinol. Invest, (1991)

[9]

Schettini G., Merola B., Miletto P., De Chiara G., Tenuta M., Caruso E., Savastano S., Tommaselli A.P., Lombardi G., Cirillo S., Lancranjan I., Long-lasting therapeutic effectiveness and improved tolerability of bromocriptine depot (Parlodel LAR) in macroprolactinomas and hyperprolactinemia, Recent Research on Clinical Endocrinology, 1, (1988)

[10]

Schettini G., Lombardi G., Merola B., Colao A., Miletto P., Caruso E., Lancranjan I., Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR), Clin. Endocrinol, 33, (1990)

← 1 2 →